Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre,open-label,randomised, phase 2 trial |
| |
| Affiliation: | 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;2. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA;3. Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA;4. Department of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA;5. Department of Obstetrics and Gynecology, Cancer Center, University of Virginia, Charlottesville, VA, USA;6. Department of Obstetrics and Gynecology, Ingram Cancer Center, Vanderbilt University Nashville, TN, USA;7. Department of Obstetrics and Gynecology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA;8. Department of Obstetrics and Gynecology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA;9. Department of Obstetrics and Gynecology, University of Wisconsin Hospital and Clinics, Madison, WI, USA;10. Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA;11. Department of Obstetrics and Gynecology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA;12. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
